Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Epigentek Group - aVenture Company Research

Epigentek Group

Epigentek Group

Epigentek, founded in 2005, is a global leader in providing innovative, efficient, and cost-effective solutions for epigenetic-related research and drug discovery.

Farmingdale, NY, US🇺🇸

Founded

Epigentek, founded in 2005, is a global leader in providing innovative, efficient, and cost-effective solutions for epigenetic-related research and drug discovery. The company's core mission is to advance the field of epigenetics by developing comprehensive and proprietary products that offer systematic solutions for researchers. Epigentek's product portfolio includes kits and reagents for DNA methylation, histone modification, RNA epigenetics, and chromatin studies, catering to academic institutions, pharmaceuticals, and biotechnology companies worldwide.

Notable affiliated individuals include leading scientists and researchers in the field of epigenetics who utilize Epigentek's products for groundbreaking studies. The company has secured investments from prominent venture capital firms specializing in biotech innovations. Key achievements include the widespread adoption of their products in esteemed research institutions and significant contributions to drug discovery processes. Epigentek's impact is evident in its facilitation of advanced epigenetic research, driving scientific discoveries and therapeutic advancements globally.

Epigentek Group - Similar Companies

EpiCypher

epicypher.com

Zymo Research

zymoresearch.com

EpigenCare

epigencare.com

Epigentek Group - Quick Facts

Who are Epigentek Group's competitors?

Companies similar to Epigentek Group include EpiCypher, Zymo Research, EpigenCare and Epigenos Biosciences.

When was Epigentek Group founded?

Epigentek Group was founded in 2005.

Where is Epigentek Group's headquarters located?

Epigentek Group's headquarters is located in Farmingdale, NY, US.

How many employees does Epigentek Group have?

Epigentek Group has 7 employees as of Feb 10, 2024.

Epigentek Group - Classification

Ownership: Public
Technology: Biotech
Geographic Exposure: Global

Revenue

Recurring
Software

Customer

Enterprise

Main Product

Research

Tags: Biotech

NAICS: 540000Professional, Scientific, and Technical Services
541500Computer Systems Design and Related Services
541000Professional, Scientific, and Technical Services
541510Computer Systems Design and Related Services
541511Custom Computer Programming Services
SIC: 7300Business Services
7370Computer Programming, Data Processing, And Other Computer Related
7371Computer Programming Services
ISIC: 7210Research and experimental development on natural sciences and engineering

Show 11 more industry codes

NAICS: 513200Software Publishers
510000Information
513000Publishing Industries
541700Scientific Research and Development Services
513210Software Publishers
541710Research and Development in the Physical, Engineering, and Life Sciences
541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC

Epigenos Biosciences

Epic-Bio

epic-bio.com

Episona

Durect

durect.com

EndGenitor Technologies

Fluidigm

standardbio.com

Quadrant Biosciences

Alida Biosciences

alidabio.com

EpiFluid

Kerafast

kerafast.com

Innovative Genetics

AtlasXomics

atlasxomics.com

8700Engineering, Accounting, Research, Management, And Related Services
8730Research, Development, And Testing Services
7372Prepackaged Software
8731Commercial Physical and Biological Research